Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Reviva Pharmaceuticals Holdings Inc RVPH

Alternate Symbol(s):  RVPHW

Healthcare Biotechnology
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.


NDAQ:RVPH - Post by User

Reviva Pharmaceuticals Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
  • UnivegoX
Post by Univegoon Apr 19, 2023 2:56am
227 Views
Post# 35402242

Countdown

Countdown

Only 8 days left!!!!

 

On 5/5/2023, there will be new data from the ongoing P3 trial and a virtual discussion, plus an expert will report on brilaroxazine (RP5063):

 

Reviva Pharmaceuticals: Brilaroxazine: a serotonin/dopamine modulator in late-stage development for Schizophrenia - LifeSci Events

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities